Inflammatory Bowel Disease

Inflammatory markers, infliximab levels, and physician global assessment scores remained similar when assessed pre- and post-switch to an infliximab biosimilar.

Dubinsky discusses the importance of head-to-head trials in IBD and looks ahead to the use of combination therapy to achieve desired treatment outcomes.

Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy.

Investigators from the guideline panel discuss the AGA’s recommendations regarding the use of fecal microbiota-based therapies for CDI, IBD, and IBS.

The guideline recommends fecal microbiota transplant in most cases of recurrent Clostridioides difficile infection but does not suggest fecal microbiota-based therapies for IBD or IBS.

Histological inflammation and clinical IBD activity were both associated with reduced fertility rates compared to histological remission and quiescent IBD.

Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations.

Remo Panaccione, MD, FRCPC, provides an overview of the newest oral therapy approved for CD, upadacitinib.

David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.

Marla Dubinsky, MD, discusses the use of off-label upadacitinib in pediatric IBD patients and the importance of this research due to delays in pediatric drug approvals.

Marla Dubinsky, MD, discusses the use of segmental intestinal ultrasound to address screen failure associated with the SES-CD in clinical trials and for detecting transmural healing.

David Rubin, MD, reviews the use of IL-12 and IL-23 inhibitors in the treatment of CD, highlighting ustekinumab and risankizumab for first-line therapy and beyond.

Experts in gastroenterology provide an overview of anti-TNF (tumor necrosis factor) and anti-integrin therapies in treatment of CD.

Patients who switched from originator adalimumab to a biosimilar experienced more treatment-emergent adverse events compared to those who stuck with the biosimilar or the reference drug.

Sara Horst, MD, MPH, and Miguel Regueiro, MD, comment on the changing treatment landscape of CD, as well as share approaches to communicate with patients about starting biologic treatment early on in CD.

Experts in gastroenterology share approaches to engaging patients in achieving treatment targets beyond symptom control.

A high intake of fish and vegetables at 1 year of age was associated with a lower risk of IBD, while consuming sugar-sweetened beverages was linked to a greater risk of developing IBD.

Experts continue the discussion on treat-to-target in CD, highlighting monitoring treatment response.

Miguel Regueiro, MD, and David Rubin, MD, review the treat-to-target strategy in relation to CD management, and how treat-to-target moves beyond symptom control.

Sara Horst, MD, MPH, comments on early introduction of biologics in the treatment of CD, highlighting her approach to initiating conversations with patients about advanced therapy.

Experts discuss the idea that, while symptoms of Crohn’s disease (CD) contribute to a patient’s quality of life, symptom control alone is not sufficient and the focus should be modifying the disease process.

Dr Sara Horst leads the discussion on the commonly followed treatment approach in the community for moderate to severe Crohn's Disease (CD) and highlights the factors that should guide treatment choices.

The past year has seen a multitude of FDA approvals, ranging from IL-23 and JAK inhibitors to biologics and subcutaneous treatment administrations, that have helped redefine what it means to treat IBD.

Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.